Adjuvant TACE Combined with Tislelizumab and Donafenib for High-Risk Hepatocellular Carcinoma After Curative Resection (TIDE): A Phase II Study

Abstract Hepatocellular carcinoma (HCC) frequently recurs after curative resection, particularly in patients with large tumors and microvascular invasion (MVI). An effective adjuvant therapy for patients with these features remains uncertain. Combining transarterial chemoembolization (TACE) with systemic therapy has shown activity in unresectable HCC, but its role after resection is unclear. Here we report a prospective, single-center, single-arm phase II study (TIDE; ChiCTR2200063003) of one postoperative TACE session followed by one year of tislelizumab and donafenib in patients with a solitary HCC larger than 5 cm and pathologically confirmed MVI. Among 30 patients, the estimated 3-year recurrence-free survival rate, the primary endpoint, was 56.7% (95% confidence interval, 37.3–72.1%) after a median follow-up of 38.7 months. The estimated 3-year overall survival rate was 93.3% (95% confidence interval, 75.9–98.3%). Grade 3 or higher treatment-related adverse events occurred in eight patients (26.7%), and there were no treatment-related deaths. This study show that adjuvant TACE combined with tislelizumab and donafenib is a feasible treatment option for HCC patients with high-risk recurrence after resection, warranting confirmation in largescale randomized clinical trials.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11550875/v1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Adjuvant TACE Combined with Tislelizumab and Donafenib for High-Risk Hepatocellular Carcinoma After Curative Resection (TIDE): A Phase II Study

Yonggang Wei, Yongjie Zhou, Wei Peng, Diao Kong et al.
7 links
Research Square
Hepatocellular Carcinoma Treatment and Prognosis
preprint

Adjuvant TACE Combined with Tislelizumab and Donafenib for High-Risk Hepatocellular Carcinoma After Curative Resection (TIDE): A Phase II Study

Yonggang Wei, Yongjie Zhou, Wei Peng, Diao Kong, Fei Xie, Tianfu Wen, Yang Zou, XiaoYun Zhang, Zheyu Chen, Junyi Shen, Minghong Yao, Chuan Li, Yufu Peng
preprint en

Abstract

Abstract Hepatocellular carcinoma (HCC) frequently recurs after curative resection, particularly in patients with large tumors and microvascular invasion (MVI). An effective adjuvant therapy for patients with these features remains uncertain. Combining transarterial chemoembolization (TACE) with systemic therapy has shown activity in unresectable HCC, but its role after resection is unclear. Here we report a prospective, single-center, single-arm phase II study (TIDE; ChiCTR2200063003) of one postoperative TACE session followed by one year of tislelizumab and donafenib in patients with a solitary HCC larger than 5 cm and pathologically confirmed MVI. Among 30 patients, the estimated 3-year recurrence-free survival rate, the primary endpoint, was 56.7% (95% confidence interval, 37.3–72.1%) after a median follow-up of 38.7 months. The estimated 3-year overall survival rate was 93.3% (95% confidence interval, 75.9–98.3%). Grade 3 or higher treatment-related adverse events occurred in eight patients (26.7%), and there were no treatment-related deaths. This study show that adjuvant TACE combined with tislelizumab and donafenib is a feasible treatment option for HCC patients with high-risk recurrence after resection, warranting confirmation in largescale randomized clinical trials.

Research Square
Sichuan University (CN), West China Hospital of Sichuan University (CN), The First People's Hospital of Neijiang (CN)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon